Bicycle Therapeutics (BCYC) Set to Release Quarterly Earnings on Thursday

Bicycle Therapeutics (NASDAQ:BCYC) is projected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Bicycle Therapeutics to announce earnings of ($0.3990) per share and revenue of $12.22 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 6:00 AM ET.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.14). Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. The firm had revenue of $0.63 million during the quarter, compared to the consensus estimate of $4.22 million. On average, analysts expect Bicycle Therapeutics to post ($2.26) EPS for the current fiscal year and ($2.27) EPS for the next fiscal year.

Bicycle Therapeutics Trading Up 2.8%

BCYC opened at $3.65 on Tuesday. The firm’s 50 day simple moving average is $3.86 and its two-hundred day simple moving average is $4.64. Bicycle Therapeutics has a 1-year low of $3.33 and a 1-year high of $9.08. The company has a market capitalization of $255.47 million, a PE ratio of -1.34 and a beta of 1.68.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on BCYC shares. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Zacks Research downgraded shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Finally, Needham & Company LLC lowered their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.86.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.